Mizuho raised the firm’s price target on Hologic (HOLX) to $70 from $65 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic upgraded to Buy from Neutral at Citi
- USPSTF ruling ‘marks the turn’ for Exact Sciences shares, says Evercore ISI
- Early notable gainers among liquid option names on May 28th
- Hologic’s Hold Rating: Balancing Potential and Risks Amidst Market Challenges
- Takeout offer validates Hologic at attractive valuation, says Raymond James